These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 9179643)

  • 21. Atypical neuroleptics: use for schizophrenia.
    Marland G
    Nurs Times; 1998 Feb 4-10; 94(5):61-2. PubMed ID: 9536768
    [No Abstract]   [Full Text] [Related]  

  • 22. [Comparison of medical and economic benefits of antipsychotics in the treatment of schizophrenia in France].
    Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
    Encephale; 2017 Aug; 43(4):311-320. PubMed ID: 27623123
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Applying Peplau's theory in improving drug compliance of a schizophrenic patient].
    Lan CM; Shiau SJ; Huang RY
    Hu Li Za Zhi; 1997 Feb; 44(1):56-62. PubMed ID: 9355386
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). How to make the decision to resort to an APAP)].
    Chéreau I; Gorwood P; Mouchabac S
    Encephale; 2009 Jan; Suppl 3():S97-100. PubMed ID: 19268186
    [No Abstract]   [Full Text] [Related]  

  • 25. Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics.
    Csernansky JG; Schuchart EK
    CNS Drugs; 2002; 16(7):473-84. PubMed ID: 12056922
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Shared decision making and long-term outcome in schizophrenia treatment.
    Hamann J; Cohen R; Leucht S; Busch R; Kissling W
    J Clin Psychiatry; 2007 Jul; 68(7):992-7. PubMed ID: 17685733
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuroleptic compliance among chronic schizophrenic outpatients: an intervention outcome report.
    Boczkowski JA; Zeichner A; DeSanto N
    J Consult Clin Psychol; 1985 Oct; 53(5):666-71. PubMed ID: 2865281
    [No Abstract]   [Full Text] [Related]  

  • 28. [Subjective well-being under antipsychotic treatment and its meaning for compliance and course of disease].
    Naber D; Lambert M; Karow A
    Psychiatr Prax; 2004 Nov; 31 Suppl 2():S230-2. PubMed ID: 15586315
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Atypical neuroleptics: autonomy and compliance?
    Marland GR
    J Adv Nurs; 1999 Mar; 29(3):615-22. PubMed ID: 10210458
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of noncompliance in patients with schizophrenia.
    Perkins DO
    J Clin Psychiatry; 2002 Dec; 63(12):1121-8. PubMed ID: 12523871
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Adherence to antipsychotic medication in schizophrenia patients].
    Baloush-Kleinman V; Poyurovsky M; Koren D; Schneidman M; Weizman A; Shnitt D
    Harefuah; 2002 Dec; 141(12):1042-9, 1090. PubMed ID: 12534202
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term phase of schizophrenia: impact of atypical agents.
    Naber D
    Int Clin Psychopharmacol; 2000 Dec; 15 Suppl 4():S11-4. PubMed ID: 11252518
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An RCT of adherence therapy for people with schizophrenia in Chiang Mai, Thailand.
    Maneesakorn S; Robson D; Gournay K; Gray R
    J Clin Nurs; 2007 Jul; 16(7):1302-12. PubMed ID: 17584349
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Psychoeducational training for schizophrenic patients: background, procedure and empirical findings.
    Hornung WP; Kieserg A; Feldmann R; Buchkremer G
    Patient Educ Couns; 1996 Dec; 29(3):257-68. PubMed ID: 9006241
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Partial compliance in schizophrenia and the impact on patient outcomes.
    Llorca PM
    Psychiatry Res; 2008 Nov; 161(2):235-47. PubMed ID: 18849080
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies.
    Kane JM
    J Clin Psychiatry; 2003; 64 Suppl 16():34-40. PubMed ID: 14680417
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New drugs for schizophrenia: an update for family physicians.
    Amadio PB; Cross LB; Amadio P
    Am Fam Physician; 1997 Sep; 56(4):1149-56, 1159-60. PubMed ID: 9310066
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Psychopharmacology: Perspectives on medication adherence and atypical antipsychotic medications.
    Velligan DI; Lam F; Ereshefsky L; Miller AL
    Psychiatr Serv; 2003 May; 54(5):665-7. PubMed ID: 12719495
    [No Abstract]   [Full Text] [Related]  

  • 39. Strategies for enhancing drug therapy of schizophrenia.
    Schooler NR; Levine J
    Am J Psychother; 1983 Oct; 37(4):521-32. PubMed ID: 6140869
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetic profile and clinical efficacy of long-acting risperidone: potential benefits of combining an atypical antipsychotic and a new delivery system.
    Ereshefsky L; Mannaert E
    Drugs R D; 2005; 6(3):129-37. PubMed ID: 15869316
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.